Can Two Ovarian Cancer Drugs Succeed Where Others Have Failed?

2

When Donna Gregory’s ovarian cancer came back for the third time, she began looking for alternatives to chemotherapy. She’d been diagnosed with stage III ovarian cancer in 2003, at age 58. After having surgery to remove her tumors, she tried platinum-based chemotherapy, but her cancer did not respond. Several more chemotherapy drugs worked, but only briefly.

Gregory searched for experimental alternatives and found a clinical trial, led by Joyce Liu, MD, at the Susan F. Smith Center for Women’s Cancers at Dana-Farber. The trial was open to women with recurrent ovarian cancer, and wasn’t restricted to BRCA mutation carriers or platinum-sensitive cancers. “I thought, oh, this is perfect for me!” she recalls.

ovarian cancer, cancer research

By combining two targeted drugs, Joyce Liu, MD, MPH helped ovarian cancer patients achieve a shrinkage in their tumors. Donna Gregory (left), shown with Ursula Matulonis, MD, has benefited from the new combination.

The trial was evaluating the effectiveness of taking two targeted drugs (agents that interfere with the biological machinery that drives tumor cell growth), and joining them as a unified force. Gregory immediately flew to Boston from her home in Miami, Fla., and enrolled. After just eight weeks on the drugs Gregory’s tumor shrank by 57 percent.

Each year in the United States, approximately 22,000 women are diagnosed with ovarian cancer. While many respond to initial chemotherapy, the cancer often comes back. Dr. Liu’s trial tested a new combination of the drug olaparib, a PARP inhibitor that compromises the way cells repair broken strands of DNA, thereby making them more vulnerable to death, with cediranib, an antiangiogenic drug that interferes with the machinery that builds new blood vessels.

Joyce Liu, MD, MPH

Joyce Liu, MD, MPH

In results reported in 2014, combining these drugs resulted in impressive activity, with tumors shrinking by more than a third in almost 80 percent of women receiving the combination. Dr. Liu is now leading additional trials that will enroll more women and compare the drug combination in a head-to-head test with the current standard of care.

While Dr. Liu’s trial was the first of its kind for ovarian cancer, it is certainly not the last. Since then, clinical researchers have begun several other trials of novel combinations in women with recurrent ovarian cancer. “We’re here to expand the options for our patients and provide treatments that are based on the genomic abnormalities of their particular cancers,” says Ursula Matulonis, MD, medical director for Gynecologic Oncology at the Susan F. Smith Center.

Read the full story in Dana-Farber’s Turning Point.

Comments Sort By Newest

2 thoughts on “Can Two Ovarian Cancer Drugs Succeed Where Others Have Failed?

  1. Would this work basically the same for someone with metastatic breast cancer and BRCA2 positive? I’m begging my doctor for a PARP, but I remain tormented by the very ineffective platinum chemo I’m on. I NEED something else but it’s hard to convince my doctor even though the cancer is progressing.

  2. Would this work basically the same for someone with metastatic breast cancer and BRCA2 positive? I’m begging my doctor for a PARP, but I remain tormented by the very ineffective platinum chemo I’m on. I NEED something else but it’s hard to convince my doctor even though the cancer is progressing.

    1. Dear Carrie —

      Thank you for your comment. We’re sorry to hear about the trouble you’ve been having. It is best to bring up this question with your doctor or oncologist, as they can provide the best advice for you.

      If you are interested in a second opinion at Dana-Farber, the procedure is the same as for becoming a new patient. If you are able to come to Boston to meet with our treatment team, please call 877-442-DFCI (877-442-3324) or fill out this online appointment request form:
      https://www.dana-farber.org/apps/request-an-appointment.aspx

      If you are not able to travel to Boston, Dana-Farber offers a program called Online Specialty Consults, which allows patients and physicians to confer with our specialists online about second opinions, treatment options, or clinical trials.

      These links provide an overview of the process:
      http://www.dana-farber.org/Partners-Online-Specialty-Consultations.aspx
      https://econsults.partners.org/v2/%28jwewk42ud2zpsevdo4p1l545%29/Tour/1.html

      I hope this is helpful and wish you all the best.

Comments are closed.

Make An Appointment

For adults: 877-960-1562

Quick access: Appointments as soon as the next day for new adult patients

For children: 888-733-4662

All content in these blogs is provided by independent writers and does not represent the opinions or advice of Dana-Farber Cancer Institute or its partners.

Latest Tweets

Dana-Farber @danafarber
Bobbi Gibson, metastatic kidney cancer patient, says it's easy to see why @DrChoueiri's nickname is "Dr. Wonderful" https://t.co/BNsRi6k4Ng
Dana-Farber @danafarber
Dr. Stephen Sallan treated Annette, 41, for acute lymphoblastic #leukemia when she was 6 mos. old. Hear the story:… https://t.co/4kRQigJrV8

Republish our posts on your blog

Interested in sharing one of our stories on your blog? Feel free to republish this content! We just ask that you credit Dana-Farber, link to the original article, and refrain from making edits that change the original context. Questions? Email the editors at insight_blog@dfci.harvard.edu.